Zelira Therapeutics Limited (ZLD.AX)
| Previous close | 0.0610 |
| Open | 0.0610 |
| Bid | 0.0600 x 14831600 |
| Ask | 0.0610 x 5161300 |
| Day's range | 0.0600 - 0.0610 |
| 52-week range | 0.0410 - 0.1400 |
| Volume | 756,442 |
| Avg. volume | 3,083,637 |
| Market cap | 71.419M |
| Beta (5Y monthly) | 1.18 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0080 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Simply Wall St.
A Quick Analysis On Zelira Therapeutics' (ASX:ZLD) CEO Compensation
Richard Hopkins has been the CEO of Zelira Therapeutics Limited ( ASX:ZLD ) since 2018, and this article will examine...
- PR Newswire
Zelira Therapeutics Expands HOPE™ Distribution in the US Through Licensing Agreement with Alternative Solutions in Washington DC
Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF), a global leader in the development of clinically validated cannabis medicines, is pleased to announce it has entered into a binding licensing agreement with Alternative Solutions, a licensed grower, manufacturer and distributor of medical cannabis products in the District of Columbia (Washington DC). Under the agreement, Alternative Solutions will produce and distribute the HOPE™ line of products, Zelira's top-selling treatment developed for autism patients, throughout the legal DC medical cannabis market beginning in Q2 2021.
- Simply Wall St.
Those Who Purchased Zelira Therapeutics (ASX:ZLD) Shares Three Years Ago Have A 48% Loss To Show For It
As an investor its worth striving to ensure your overall portfolio beats the market average. But its virtually certain...
